Shares of Galera Therapeutics (NASDAQ:GRTX) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.
Brokerages have set a one year consensus target price of $15.00 for the company, according to Zacks. Zacks has also given Galera Therapeutics an industry rank of 59 out of 255 based on the ratings given to its competitors.
Several brokerages recently weighed in on GRTX. Bank of America started coverage on shares of Galera Therapeutics in a research note on Monday. They set a “buy” rating and a $15.00 target price on the stock. Citigroup began coverage on shares of Galera Therapeutics in a research report on Monday. They issued a “buy” rating and a $20.00 price target for the company. BTIG Research initiated coverage on shares of Galera Therapeutics in a research note on Monday. They issued a “buy” rating and a $30.00 price target for the company. Finally, Credit Suisse Group initiated coverage on Galera Therapeutics in a research report on Monday. They set a “neutral” rating and a $14.00 price objective on the stock.
In other Galera Therapeutics news, major shareholder Enterprise Associates 14 New purchased 416,666 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was bought at an average cost of $11.79 per share, with a total value of $4,912,492.14. Also, insider Holdings A/S Novo acquired 500,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average cost of $12.76 per share, with a total value of $6,380,000.00.
Galera Therapeutics stock traded down $0.05 during mid-day trading on Tuesday, hitting $12.02. The company’s stock had a trading volume of 68,877 shares, compared to its average volume of 115,240. Galera Therapeutics has a 1 year low of $11.50 and a 1 year high of $14.88.
About Galera Therapeutics
Galera Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis.
Featured Story: QQQ ETF
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.